Evidence map›Paper›PMID 41262039›Full record

ArticleHaematologica2026

Multicenter upfront randomized phase II trial of quizartinib and high-dose cytarabine plus mitoxantrone in relapsed/refractory acute myeloid leukemia with FMSlike tyrosine kinase 3 internal tandem duplication.

Sonia Jaramillo, Johannes Krisam, Lucian Le Cornet, Markus Kratzmann, Lukas Baumann, Sabine Kayser, Christoph Schliemann, Martin Kaufmann, Meinhard Kieser, Uwe Platzbecker and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The best laid schemes...Haematologica · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sonia JaramilloDepartment of Internal Medicine V, Heidelberg University Hospital.
Johannes KrisamInstitute of Medical Biometry, University of Heidelberg.
Lucian Le CornetClinical Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center.
Markus KratzmannClinical Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center.
Lukas BaumannInstitute of Medical Biometry, University of Heidelberg.
Sabine KayserDepartment of Medicine I - Hematology and Cell Therapy, Leipzig University Hospital.
Christoph SchliemannDepartment of Medicine A, Münster University Hospital.
Martin KaufmannDepartment of Hematology, Oncology and Palliative Medicine, Robert-Bosch Hospital Stuttgart.
Meinhard KieserInstitute of Medical Biometry, University of Heidelberg.
Uwe PlatzbeckerDepartment of Medicine I - Hematology and Cell Therapy, Leipzig University Hospital.
Carsten Müller-TidowDepartment of Internal Medicine V, Heidelberg University Hospital.
Richard F SchlenkDepartment of Internal Medicine V, Heidelberg University Hospital, Germany; Clinical Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center. richard.schlenk@nct-heidelberg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41262039
PMCPMC13231092

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.